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A variety of receptors on pancreatic acinar and duct cells regulate both pancreatic exocrine
secretion and intracellular processes. These receptors are potential sites ofaction for therapeu-
tic agents in the treatment ofpancreatitis.
Cholecystokinin (CCK) receptor antagonists, which may reduce the level of metabolic
"stress" on acinar cells, have been shown to mitigate the severity of acute pancreatitis in a
number of models. Not all studies have shown a benefit, however, and differences may exist
between different structural classes of antagonists. Because increased pancreatic stimulation
due to loss offeedback inhibition ofCCK has been proposed to contribute to the pain of some
patients with chronic pancreatitis, CCK receptor antagonists could also be of benefit in this
setting.
Somatostatin and its analogs diminish pancreatic secretion ofwaterand electrolytes and have
been effective in treating pancreatic fistulas and pseudocysts. These agents are also being
evaluated for their ability to reduce pain in chronic pancreatitis (perhaps by reducing ductal
pressure by diminishing secretory volume) and mitigating the severity of acute pancreatitis
(possibly by reducing the metabolic load on acinar cells).
Recently described secretin receptor antagonists may also have therapeutic value as a means
ofselectively inhibiting pancreatic secretion ofwater and electrolytes.
Potent agonists and antagonists are becoming increasingly available for receptors
involved in regulating the function of the gastrointestinal tract, including the
exocrine pancreas. One ofthe first applications ofsuch agents to clinical practice has
been the use of secretin with or without cholecystokinin (CCK) or its analog
caerulein in testing pancreatic exocrine secretory function [1]. More recently, the
development ofCCK and secretin receptor antagonists and ofoctreotide, a clinically
useful analog of somatostatin, has raised the prospect that therapies directed at
modulating hormonal regulation of the pancreas may prove useful in treating acute
or chronic pancreatitis.
CCK RECEPTOR ANTAGONISTS
Evidence that CCK may contribute to the severity of acute pancreatitis has come
from a report in which caerulein, a CCK analog, was described as worsening the
severity and mortality ofacute pancreatitis produced in rats by intraductal injections
ofbile salts [2] and from numerous studies in the rat (e.g., [3]) and the mouse (e.g.,
[4]) in which supramaximal stimulation with caerulein produced acute pancreatitis.
Suchfindings suggested that CCK receptorblockade might have a beneficial effect in
mitigating the severity ofacute pancreatitis.
At least in the rat, caerulein-induced acute pancreatitis appears to be due to the
interaction of caerulein with a low-affinity CCK receptor which is involved in
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FIG. 1. Theglutaramic acid-derivative CCKreceptor antago-
nist CR-1392 reduced the severity of caerulein-induced acute
pancreatitis in rats (as indicated by serum amylase activity)
when given after the initiation ofpancreatitis (solid circles) and
prevented pancreatitis when given in a large dose prior to its
initiation (open circles), compared to control animals receiving
caerulein alone (open squares) (from [6], reprinted with permis-
sion).
high-dose inhibition ofenzyme secretion by the pancreas [5]. CCK receptor antago-
nistswould thusbeexpected to reduce the severityofacutepancreatitis or, ifgiven as
apre-treatment in sufficient amount, toprevent it. This result is indeed the case (Fig.
1) [4,6].
It is hardly surprising that a CCKreceptor antagonist can prevent acute pancreati-
tis produced by excessive stimulation with a CCK analog. A more intriguing
observation was the finding that proglumide (a glutaramic acid-derivative CCK
receptor antagonist) reduced the severity of injury and significantly improved
survival in a necrotizing, highly lethal form of pancreatitis produced in mice by
feeding acholine-deficient, ethionine-supplemented (CDE) diet [7]. Proglumidewas
effective whether administered prior to or following initiation of acute pancreatitis
(Fig. 2), under conditions in which plasma CCK levels were not elevated [7]. Similar
effects in CDE diet-induced acute pancreatitis have been reported for the more
potent glutaramic acid-derivative CCK receptor antagonist lorglumide (CR-1409)
[8].
Direct beneficial effects of CCK receptor antagonists have also been reported in
other models ofacute pancreatitis which do not involve supramaximal stimulation of
the pancreas by CCK, caerulein, or other ligands which bind to the CCK receptor.
Glutaramic acid-derived antagonists mitigated the severity of acute pancreatitis
produced in rats by supramaximal stimulation with a cholinergic agonist [9] or by
direct injection of taurocholate into the pancreatic parenchyma [10]. Members of a
different structural class of CCK receptor antagonist (asperlicin and its derivatives,
related structurally to the benzodiazepines) improved survival and reduced the
biochemical and morphological severity in experimental acute pancreatitis produced
by perfusion of the pancreatic duct by sodium taurocholate in the rat [11,12] or by
mechanical trauma in the guinea pig [12].
Other recent reports provide indirect support for the hypothesis that CCK is an
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FIG. 2. The glutaramic acid-derivative CCKreceptor antago-
nist proglumide improved survival in CDE diet-induced acute
pancreatitis in mice compared to controls (saline), whether
administered before (proglumide A) or after (proglumide B)
the onset of pancreatitis. The protective effect of proglumide
was completely reversed when CCK was given at a dose which
does not, in itself, produce pancreatitis (proglumide A + CCK-
8) (from [7], reprinted with permission).
important factor in the pathophysiology of acute pancreatitis. Fasted rats had a
reduction inplasma CCKconcentration and less severe caerulein-induced pancreati-
tis than didfed rats [13]. Asimilar degree ofimprovement wasobservedwhenthefed
rats were treated with the CCK receptor antagonist loxiglumide (a glutaramic acid
derivative). In another report [14], the severity of CDE diet-induced pancreatitis in
mice was markedly reduced by feeding animals taurocholate, a bile salt which
reduces plasma CCK levels by inhibiting CCK release from the small intestine (Fig.
3). Conversely, bile salt depletion by feeding cholestyramine led to an increase in
plasma CCK concentration and worsened pancreatitis. This deleterious effect of
cholestyramine could be blocked by administration of loxiglumide, just as the
beneficial effects oftaurocholate feeding could be blocked bygiving animals CCK.
Not all studies, however, have observed beneficial effects of CCK receptor
antagonists in experimental models of acute pancreatitis. Administration of the
asperlicin derivative devazepide (formally designated as MK-329 or L-364,718), one
of the most potent inhibitors of CCK-stimulated enzyme secretion by the pancreas,
failed to show a beneficial effect in CDE diet-induced pancreatitis even at doses
whichmarkedlyreduced the severityofcaerulein-induced pancreatitis [15,16]. Other
investigators did notobserve abeneficial effectofloxiglumidewhengiven to ratswith
acute pancreatitis induced by taurocholate infusion into the pancreatic duct [17].
Thus far the conflicting data resulting from the use of different CCK receptor
antagonists in different models of acute pancreatitis have defied explanation. Posi-
tive results have, however, now been reported by at least five different groups of
investigators, usingfourdifferentmodels (caerulein stimulation, CDEdiet, taurocho-
late perfusion of the pancreatic duct, and trauma) in three different species (rat,
mouse, and guinea pig). This result warrants further investigation in experimental
systems and consideration of clinical trials. The striking differences observed in the
CDE diet model between glutaramic acid derivatives such as proglumide and the
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FIG. 3. a. In CDE diet-induced acute pancre-
atitis in mice, taurocholate feeding decreased
plasma CCK levels and improved survival com-
pared to the control. Conversely, cholestyramine
feeding increased plasma CCK levels and de-
creased survival. b. The protective effect of
taurocholate feeding was reducedwhen CCK was
administered (taurocholate + CCK-8), whereas
administration of the glutaramic acid-derived
CCK receptor antagonist lorglumide (cholestyr-
amine + CR-1409) improved survival in choles-
tyramine-fed animals. These findings suggest that
CCK is contributing to the severity of the acute
pancreatitis produced in this model (from [14],
reprinted with permission).
asperlicin derivative devazepide suggest that the beneficial effects ofthe former may
be regulated by blockade of a CCK receptor unrelated to stimulation of digestive
enzyme secretion by the acinar cell but, perhaps, regulating intracellular metabolism
in some way. Thus the action of proglumide and related CCK receptor antagonists
might be to put the acinar cell "metabolically at rest."
Another potential clinical use for CCK receptor antagonists may be in the
treatment ofthe pain resulting from chronic pancreatitis ifthe level ofpain is related
in some patients to the level of acinar cell metabolic activity or digestive enzyme
secretion. Treatment with high doses of pancreatic enzyme supplements have been
reported to reduce pain in some patients with chronic pancreatitis [18]. This effect
has been hypothesized to be due to enhancement of serine protease-mediated
feedback inhibition of CCK secretion by the proximal small intestine. If this
explanation proves to be correct, administration of CCK receptor antagonists would
be expected to provide a more consistent and, perhaps, greater, beneficial effect.
Unfortunately, despite these tantalizing prospects for the use of CCK receptor
antagonists in acute or chronic pancreatitis, their ultimate clinical value (if any)
remains to be established.
SOMATOSTATIN ANALOGS
A peptide agonist already in clinical use is the somatostatin analog octreotide,
which has proven effective in the treatment of some pancreatic fistulas [19] and
pseudocysts [20], presumably primarily through diminishing water and electrocyte
secretion by centroacinar and ductal epithelial cells in the pancreas. Octreotide is
also being evaluated as a therapeutic agent to reduce pain in chronic pancreatitis in
the hope that a decrease in thevolume ofpancreatic secretion will lead to diminished
pain by decreasing the pressure in the pancreatic duct system. Ifthis theory turns out
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to be validated, clinical development ofrecently described secretin receptor antago-
nists [21] could prove to be as effective as octreotide but more selective.
Somatostatin and its analogs have also been proposed for use in the treatment of
acute pancreatitis [22], with the rationale being either to reduce pancreatic enzyme
secretion or to lessen the metabolic workload of acinar cells (a beneficial effect also
hypothesized for CCK receptor antagonists). The clinical data are as yet too limited
to determine whether this approach will be successful. If it is, however, it is more
likely that the second rationale will account for its success rather than the first,
because pancreatic enzyme secretion appears to be markedly reduced during the
development ofacutepancreatitis even in theabsence ofanypharmacologicinterven-
tion [23,24].
CONCLUSION
The increasing availability of potent and specific agonists and antagonists for
regulatory gastrointestinal peptides now opens the way for studies evaluating the
extent to which disordered regulatory processes are involved in the development of
diseases of the pancreas. In addition, these agents provide the possibility that
pancreatic inflammation (both acute and chronic) and its consequences could be
treated more directly and effectively than is now possible.
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